BiotechTube
IRBM

IRBM

Pomezia, Italy· Est.
irbm.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Founded in 1998, IRBM has established itself as a premier Italian CRO specializing in early-stage drug discovery, with capabilities spanning small molecules, AI/ML, proteomics, and functional genomics. The company operates a services-based business model, generating revenue by partnering with external clients while also developing its own internal assets. Recent milestones include a breakthrough in Zika virus drug discovery, expansion of its genomic platform, and recognition for sustainability, positioning it as a strategic partner in navigating the complex R&D pathway.

OncologyInfectious Diseases

Technology Platform

Integrated drug discovery platform combining medicinal chemistry, biology, computational sciences (AI/ML), proteomics (including Bruker rapifleX MALDI Tissuetyper), functional genomics, and CRISPR/Cas9 gene editing. Focus on covalent inhibitors, targeted protein degradation, and compound management automation.

Funding History

1
GrantUndisclosed

Opportunities

The growing trend of pharma outsourcing early-stage R&D presents a sustained demand for high-quality CRO services.
IRBM's internal asset development, particularly in areas like Zika virus and novel oncology targets, offers significant upside potential through future licensing or partnership deals.
Expansion of its AI and functional genomics platforms allows it to address the increasing need for data-driven de-risking in drug discovery.

Risk Factors

IRBM faces intense competition from larger, global CROs and is susceptible to client concentration risk.
The proprietary drug development pipeline carries the inherent high failure rate of preclinical research, which could impact resource allocation and reputation.
Geographic concentration in Italy, while mitigated by global clients, presents potential operational and economic risks.

Competitive Landscape

IRBM competes in the global CRO market against large players like Charles River, Evotec, and WuXi AppTec, as well as specialized discovery firms. Its differentiation lies in its deep integrated expertise in specific modalities (covalent inhibitors, proteomics), its hybrid model of service and proprietary work, and its recognition as a leading Italian scientific hub. The competitive landscape requires continuous technological investment to maintain an edge.

More companies in Small Molecule Drugs →More companies in Italy →